Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1996 2
1997 1
1999 2
2000 2
2002 3
2003 2
2004 1
2005 4
2006 1
2007 2
2008 1
2009 1
2010 3
2011 3
2012 2
2024 0

Text availability

Article attribute

Article type

Publication date

References for this PMC Article for PMID: 22845909

31 results

Results by year

Filters applied: . Clear all
Page 1
A novel monoclonal antibody to CD40 prolongs islet allograft survival.
Lowe M, Badell IR, Thompson P, Martin B, Leopardi F, Strobert E, Price AA, Abdulkerim HS, Wang R, Iwakoshi NN, Adams AB, Kirk AD, Larsen CP, Reimann KA. Lowe M, et al. Am J Transplant. 2012 Aug;12(8):2079-87. doi: 10.1111/j.1600-6143.2012.04054.x. Epub 2012 May 8. Am J Transplant. 2012. PMID: 22845909 Free PMC article.
Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates.
Badell IR, Thompson PW, Turner AP, Russell MC, Avila JG, Cano JA, Robertson JM, Leopardi FV, Strobert EA, Iwakoshi NN, Reimann KA, Ford ML, Kirk AD, Larsen CP. Badell IR, et al. Am J Transplant. 2012 Jan;12(1):126-35. doi: 10.1111/j.1600-6143.2011.03736.x. Epub 2011 Sep 15. Am J Transplant. 2012. PMID: 21920020 Free PMC article.
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F. Vanrenterghem Y, et al. Transplantation. 2011 May 15;91(9):976-83. doi: 10.1097/TP.0b013e31820c10eb. Transplantation. 2011. PMID: 21372756 Clinical Trial.
LFA-1-specific therapy prolongs allograft survival in rhesus macaques.
Badell IR, Russell MC, Thompson PW, Turner AP, Weaver TA, Robertson JM, Avila JG, Cano JA, Johnson BE, Song M, Leopardi FV, Swygert S, Strobert EA, Ford ML, Kirk AD, Larsen CP. Badell IR, et al. J Clin Invest. 2010 Dec;120(12):4520-31. doi: 10.1172/JCI43895. Epub 2010 Nov 22. J Clin Invest. 2010. PMID: 21099108 Free PMC article.
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B. Larsen CP, et al. Transplantation. 2010 Dec 27;90(12):1528-35. doi: 10.1097/TP.0b013e3181ff87cd. Transplantation. 2010. PMID: 21076381
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. Vincenti F, et al. Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x. Am J Transplant. 2010. PMID: 20415897 Free article. Clinical Trial.
Isotype selection in antibody engineering.
Salfeld JG. Salfeld JG. Nat Biotechnol. 2007 Dec;25(12):1369-72. doi: 10.1038/nbt1207-1369. Nat Biotechnol. 2007. PMID: 18066027 Review. No abstract available.
31 results